First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Tae Won KimHoward A BurrisMaria J de Miguel LukenMichael J PishvaianYung-Jue BangMichael S GordonAhmad AwadaD Ross CamidgeF Stephen HodiGrant A McArthurWilson H MillerAndres CervantesLaura Q M ChowAlexander M LesokhinAnnemie RuttenMario SznolDeepali RishipathakShang-Chiung ChenEric G StefanichTony PourmohamadMaria AndersonJeong KimMahrukh HuseniIna RheeLillian L SiuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Although objective responses were rarely observed with MOXR0916 monotherapy, the favorable safety profile and evidence of tumor immune activation in a subset of patients support further investigation in combination with complementary agents such as PD-1/PD-L1 antagonists.